CD44 and myeloproliferative neoplasm: In the present study, we found that CD34+/CD38− MPN NSC display numerous 'therapeutic' targets, including CD33, CD44, CD47, CD97, CD99, CD117, CD123, CD133, CD184, and CD274 (PD‐L1) independent of the type of MPN or molecular driver lesion.